重组人可溶性血管内皮细胞生长抑制因子体外抗血管内皮细胞增殖的活性

目的：研究重组人可溶性血管内皮细胞生长抑制因子（VEGI）体外抗血管内皮细胞增殖的活性。方法：MTT法检测重组人可溶性VEGI对血管内皮细胞及肿瘤细胞增殖的抑制活性。结果：在体外，重组人可溶性BEGI可强烈抑制人脐静脉内皮细胞ECV304、大鼠肺源毛细血管内皮细胞（MPCEC）及新生牛主动脉内皮细胞（BAEC）的增殖，不能报制黑色素瘤细胞B－16和小鼠成纤维细胞L－929的增殖。结论：重组人可溶性VEGI能作用于不同来源的血管内皮细胞,而对肿瘤细胞增殖无抑制作用，提示其可能通过抗肿瘤新生血管生成而发挥抗肿瘤作用。

Growth Inhibitor on the Proliferation of Vascular Endothelial Cells in vitro

Objective\ To test the recombinant soluble vascular endothelial growth inhibitor(\{VEGI\}) for its inhibition activity against the proliferation of new\|born bovine aortic endothelial cells(BAEC), human umbilical vein endothelial cell line ECV304 and mouse pulmonary capillary endothelial cells(MPCEC), B\|16 melanoma cells and L\|929 fibroblast in vitro.\ Methods\ The effects of recombinant VEGI on the proliferation of vascular endothelial cells and tumor cells were assayed by MTT technique in vitro.\ Results\ The recombinant VEGI inhibited the proliferation of BAEC, ECV304 and MPCEC in vitro in a dose\|dependent manner.\ In contrast, recombinant VEGI had no influence on the growth of B\|16 and L\|929 cells under the same culture conditions.\ Conclusion\ The recombinant soluble VEGI could specifically inhibit the proliferation of endothelial cells but could not inhibit the proliferation of tumor cells in vitro.\ This data suggest that VEGI might be highly valuable to angiogenesis inhibition based cancer therapy.